secwatch.observer — SEC 8-K summary
======================================

Issuer:     Journey Medical Corp (DERM)
CIK:        0001867066
Form:       8-K
Filed at:   2023-03-29T23:59:59+00:00
Accession:  0001104659-23-038309
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Journey Medical reports record FY22 revenue of $73.7M (+17% YoY); net loss narrows to $29.6M
--------------------------------------------------------------------------------

- Record total revenues of $73.7M for FY2022, up 17% from $63.1M in FY2021.
- Net loss of $29.6M ($1.69/share) vs $44.0M ($4.32/share) in prior year; Adjusted EBITDA -$7.3M.
- Phase 3 DFD-29 (rosacea) fully enrolled; topline data expected H1 2023; NDA filing H2 2023.
- Q4 2022 revenue $16.0M, down 9% YoY due to Targadox generic competition.
- SG&A expenses rose to $59.5M from $39.8M; R&D decreased to $10.9M from $16.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867066/000110465923038309/0001104659-23-038309-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867066/000110465923038309/tm236285d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-038309

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer